Responses
Immune cell therapies and immune cell engineering
Original research
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Compose a Response to This Article
Other responses
No responses have been published for this article.